



Supplementary Materials for

Structural Basis for Membrane Anchoring of HIV-1 Envelope Spike

Jyoti Dev^{1,5#}, Donghyun Park^{2#}, Qingshan Fu¹, Jia Chen^{2,3}, Heather Jiwon Ha^{2,3}, Fadi Ghantous⁴, Tobias Herrmann⁵, Weiting Chang², Zhijun Liu⁶, Gary Frey^{2,3}, Michael S. Seaman⁴, Bing Chen^{2,3*} and James J. Chou^{1,6}

correspondence to: bchen@crystal.harvard.edu

This PDF file includes:

Materials and Methods

Figures S1 to S20

Table S1 and S4

References

Materials and Methods

Protein expression and purification

HIV-1 gp41(677-716) fragments from the clade C isolate 92BR025.9 (with M687K mutation), the clade D 92UG024.2 (designated gp41^{HIV1D(677-716)}) and the clade G 92RU131.16 were synthesized by GenScript (Piscataway, NJ). Expression constructs were created by fusing the gp41(677-716) fragments to the C-terminus of the His9-TrpLE expression sequence in pMM-LR6 vector (a gift from S.C. Blacklow, Harvard Medical School), with an added methionine in-between for cleavage by cyanogen bromide. Constructs with mutations in the TMD were generated by standard PCR protocols and confirmed by DNA sequencing. For NMR sample preparation, transformed *E. coli* strain BL21 (DE3) cells were grown in 1L M9 minimal media supplemented with Centrum multivitamins and stable isotopes. Cultures were grown at 37°C to an absorbance of ~0.7 at 600 nm, and cooled to 18°C before induction with 500 µM isopropyl β-D-thiogalactopyranoside at 18°C for overnight. For fully deuterated proteins, bacterial cultures were grown in D₂O (Sigma Aldrich, St. Louis, MO) with deuterated glucose (Cambridge Isotope Laboratories, Tewksbury, MA).

Cells were harvested after overnight growth, suspended in a lysis buffer (50 mM Tris, pH 8.0 and 200 mM NaCl), and lysed by sonication. Inclusion bodies were separated by centrifugation at 8,000 xg and suspended in a denaturing buffer (1% Triton X-100, 6 M guanidine hydrochloride, 50 mM Tris, pH 8.0 and 200 mM NaCl). The fusion protein was bound to nickel affinity resin (Sigma Aldrich), washed with a washing buffer (8M Urea, 50 mM Tris, pH 8.0 and 200 mM NaCl) and deionized H₂O, and finally eluted with 90% formic acid. The HIV-1 gp41(677-716) protein was released from the 14-kilodalton TrpLE by cleavage at the methionine using cyanogen bromide (0.1g/ml) in 90% formic acid for 1 hr. The cleavage reaction mixture was then dialyzed to remove excess cyanogen bromide and lyophilized. Proteins were dissolved in 90% formic acid and separated by reverse-phase high performance liquid chromatography (RP-HPLC) in a Zorbax SB-C3 column (Agilent Technologies, Santa Clara, CA) with a gradient from 5% isopropanol (0.1% trifluoroacetic acid) to 75% isopropanol and 25% acetonitrile (0.1%

trifluoroacetic acid). Fractions containing the HIV-1 gp41(677-716) protein were collected, lyophilized. Protein identity was confirmed by MALDI-TOF mass spectrometry and SDS-PAGE.

Reconstitution of HIV-1 gp41(677-716) in bicelles

To reconstitute in bicelles, 1-2 mg of lyophilized HIV-1 gp41(677-716) protein was mixed with 12 mg 1,2-Dimyristoyl-*sn*-Glycero-3-Phosphocholine (DMPC; protonated from Avanti Polar Lipids, Alabaster, AL or deuterated from FB Reagents, Boston, MA) and ~30 mg 1,2-Dihexanoyl-*sn*-Glycero-3-Phosphocholine (DHPC; protonated from Avanti Polar Lipids or deuterated from FB Reagents). The mixture was then dissolved in 3 ml of 8 M Urea, and dialyzed twice against 25 mM MES buffer (pH 6.7) to remove the denaturant. Since some DHPC was lost during dialysis, it was added back after dialysis to make the final DMPC: DHPC ratio ~1:2. The DMPC:DHPC ratio was monitored by 1D NMR throughout the reconstitution process and verified in the final NMR sample. The sample was concentrated using Centricon (EMD Millipore, Billerica, MA) to ~300 μ l. The final NMR sample contains ~0.8 mM monomeric HIV-1 gp41(677-716) protein, 60 mM DMPC, 120 mM DHPC, 25 mM MES (pH 6.7), 0.1% NaN₃ and 6% D₂O. For NOESY experiments, the protein was reconstituted in DMPC and DHPC with deuterated acyl chains.

NMR spectroscopy

All NMR data was collected at 30°C on Bruker spectrometers operating at ¹H frequency of 900 MHz, 750 MHz, or 600 MHz and equipped with cryogenic probes. NMR data was processed using NMRPipe (36) and spectra analysis was performed in NMRPipe, CCPNMR (37) and XEASY (38).

Sequence-specific assignments of backbone amide resonance were determined from two pairs of gradient-selected, TROSY-enhanced triple resonance experiments (39), collected on a uniformly (¹⁵N, ¹³C, ²H)-labeled sample using 750 MHz spectrometer. The triple resonance experiments included HNCA, HN(CO)CA, HN(CA)CO and HNCO. Backbone amide resonance assignments were confirmed in a ¹⁵N-edited NOESY-TROSY-HSQC

spectrum with 100ms NOE mixing time (τ_{NOE}), which was recorded on a 900 MHz spectrometer on uniformly (^{15}N , ^{13}C)-labeled sample. The ^{15}N -edited NOESY-TROSY-HSQC ($\tau_{\text{NOE}} = 100\text{ms}$) and ^{13}C -edited NOESY-HSQC ($\tau_{\text{NOE}} = 150\text{ms}$) were used to assign protein aliphatic and aromatic side chain resonances. Stereospecific assignments of methyl groups were determined from a constant-time (28 ms) ^1H - ^{13}C HSQC spectrum recorded on a 15% ^{13}C -labeled sample.

Intramolecular distance restraints derived from nuclear Overhauser enhancements (NOEs) were obtained from the above mentioned ^{15}N -edited and ^{13}C -edited NOESY experiments. A combination of intramolecular distance restraints and backbone dihedral angles, obtained from chemical shifts, were used to define the helical region of the monomer. Determining the intermolecular distance restraints faced the challenge of measuring NOEs between structurally equivalent subunits having the same chemical shifts. To solve this problem, we prepared mixed sample in which half of the monomers were ^{15}N , ^2H -labeled and the other half 15% ^{13}C -labeled. Recording a 3D ^{15}N -edited NOESY-TROSY-HSQC ($\tau_{\text{NOE}} = 300\text{ ms}$) on this sample allowed measurement of exclusive NOEs between the ^{15}N -attached protons of one subunit and aliphatic protons of the neighboring subunits. The non-deuterated peptide was 15% ^{13}C -labeled for recording the ^1H - ^{13}C HSQC spectrum as internal aliphatic proton chemical shift reference. An additional ^{15}N -edited NOESY spectrum ($\tau_{\text{NOE}} = 60\text{ ms}$) was recorded on a ^{15}N -labeled sample to assign $\text{H}\epsilon$ - $\text{N}\epsilon$ resonances of arginine and confirm presence of water NOE to arginine $\text{H}\epsilon$ - $\text{N}\epsilon$.

Structure calculation

Structure was calculated using the program XPLOR-NIH (40). First, the monomer structure was derived using intramonomer restraints and backbone dihedral restraints, determined from chemical shifts using the TALOS+ program (41). The dihedral restraints and uncertainties from TALOS+ program were used as restraints in XPLOR calculation because the statistics for N, $\text{C}\alpha$ and C' chemical shift derived ϕ and ψ were considered “good” by TALOS+ (except for G711 and L715, which were not used) (Fig. S18). In total, 10 monomer structures were calculated using a standard simulated annealing (SA)

protocol. We then used three copies of the lowest energy monomer structure to construct an initial model of the trimer using intermonomer distance restraints from the NOESY experiment collected on mixed samples. For each intermonomer restraint between two adjacent monomers, three identical distance restraints were assigned respectively to all pairs of neighboring monomers to satisfy the condition of C3 rotational symmetry. The assembled trimer was then refined against the complete set of NOE restraints (both intramonomer and intermonomer) and dihedral angles using a SA protocol in which the temperature in the bath was cooled from 1000K to 20K. The NOE restraints were enforced by flat-well harmonic potentials, with the force constant ramped from 25 to 50 kcal/mol Å⁻² during annealing. For the defined helical regions, backbone dihedral angle restraints ($\Phi = -60^\circ$, $\Psi = -40^\circ$) were applied, all with a flat-well ($\pm 10^\circ$) harmonic potential with force constant ramped from 15 to 30 kcal/mol rad⁻². A total of 75 structures were calculated and 15 lowest energy structures were selected as the final structural ensemble. The assignment completeness for different nuclei are: N, 92.5%; H, 94.87%; CO, 97.50%; CA, 97.50%; HA, 95.35%; Methyl C, 97.30%; Methyl H, 97.30%; all other H - 71.95%. Additional data are also shown in Figs. S19 and S20.

Generation of Env mutant constructs and production of monoclonal antibodies

Full-length Env mutants were generated using the 92UG037.8 or C97ZA012 gp160, described previously (13), as a template by QuikChange Site-Directed Mutagenesis (Agilent Technologies). All constructs were confirmed by restriction digestion and DNA sequencing. Anti-HIV-1 Env monoclonal antibodies and their Fab fragments were produced as described (13, 42). We have generated expression constructs of antibodies PG9, PG16, PGT145 and 10E8 using synthetic genes made by GeneArt Gene Synthesis (Life Technologies, Carlsbad, CA) or GenScript. The VRC01 expression construct was kindly provided by John Mascola (VRC, NIH); antibodies 10-1074 and 3BNC117 by Michel Nussenzweig (Rockefeller University); the CHO stable line expressing antibody b6 by Dennis Burton (Scripps); 17b hybridoma by James Robinson (Tulane University); 3791 hybridoma by Susan Zolla-Pazner (New York University). The expression constructs of 10E8 were initially obtained from the NIH AIDS reagent program.

Production of pseudoviruses containing mutant Envs

Preparation of HIV-1 Env pseudoviruses containing mutations in the TMD, titration of pseudovirus stocks to determine the 50% tissue culture infectious dose per ml (TCID₅₀/ml) and dilution for use in neutralization assays were performed as previously described (43). Briefly, each pseudovirus was prepared by transfecting 293T/17 cells (ATCC, Manassas, VA) with 4 µg of Env expression plasmid and 8 µg of an Env-deficient HIV-1 backbone vector (pSG3ΔEnv). Pseudovirus-containing culture supernatant was harvested 24 hours after transfection, filtered (0.45 µm), and stored at –80°C. To determine TCID₅₀/ml, a 5-fold serial dilution of virus stock was performed in quadruplicate wells and incubated with TZM.bl cells (NIH AIDS reagent program) in growth media containing DEAE-dextran (Sigma-Aldrich) at a final concentration of 11 µg/ml. After 48 hours, the cells were measured for luciferase reporter gene expression, indicating the ability of the pseudovirus to infect cells. TCID₅₀/ml was calculated using an Excel macro made available on the Las Alamos National Laboratories website (www.hiv.lanl.gov).

HIV-1 p24 Antigen ELISA assay

Viral stocks were boiled in a buffer containing 0.5% Triton X-100 for 60 min and analyzed for p24 antigen using a HIV-1 p24 antigen ELISA 2.0 kit (ZeptoMetrix Corporation, Buffalo, New York). Briefly, virus samples were diluted with the assay diluent provided in the kit, loaded in duplicate onto a prewashed plate, and incubated at 37°C for 2 hr. The plate was then washed 6 times with 1X washing buffer, and incubated with an anti-p24 antibody conjugated with horseradish peroxidase for 1 hr. Substrate (tetramethylbenzidine) was then added to the wells, and incubated for 30 min at room temperature. Colorimetric reaction was terminated by addition of hydrochloric stop-solution (hydrochloric), and optical density (OD) was recorded at 450 nm using an Emax Precision Microplate Reader (Molecular Devices, LLC, Sunnyvale, CA).

Western blot

293T cells were transiently transfected with 5 µg of the 92UG037.8 gp160 expression construct or its TMD mutants. Lysates of cells expressing Env or its mutants were

prepared by resuspending the cells in PBS (phosphate buffered saline) at a density of 2×10^6 cells/ml, followed by treatment with Laemmli Sample Buffer (Bio-Rad, Hercules, CA) and boiling for 10 min. Virus lysates were made by directly mixing p24-normalized virus stocks with Laemmli Sample Buffer and boiling for 10 min. Env samples were resolved in 4-15% Mini-Protean TGX gel (Bio-Rad) and transferred onto PVDF membranes (Millipore, Billerica, MA) by an Iblot2 (Life Technologies). Membranes were blocked with 5% skimmed milk in PBS for 1 hour and incubated with anti-V3 loop antibody 3791 for another hour at room temperature. Alkaline phosphatase conjugated anti-human Fab IgG (1:5000) (Sigma-Aldrich) was used as a secondary antibody. Env proteins were visualized using one-step NBT/BCIP substrates (Thermo Scientific, Cambridge, MA).

Flow cytometry

293T cells were transiently transfected with 2 μ g of the 92UG037.8 gp160 expression construct or its TMD mutants in 6 wells plates. Env-expressing cells were detached from plates using PBS, and washed with ice-cold PBS containing 1% BSA. 10^6 cells were incubated for 30~40 minutes on ice with either VRC01 Fab, 2G12 Fab, or 10e8 IgG at concentrations of 10 μ g/ml in PBS containing 1% BSA. The cells were then washed twice with PBS containing 1% BSA and stained with R-Phycoerythrin AffiniPure F(ab')₂ fragment goat anti-human IgG, F(ab')₂ Fragment specific secondary antibody (Jackson ImmunoResearch laboratories, West Grove, PA) at 5 μ g/ml. All the fluorescently labeled cells were washed twice with PBS containing 1% BSA and analyzed immediately using a BD LSRII instrument and program FACSDIVA (BD Biosciences, San Jose, CA). All data were analyzed by FlowJo (FlowJo, LLC, Ashland, OR).

Cell-cell fusion assay and antibody inhibition

We have adapted an assay, based on the α -complementation of *E. coli* β -galactosidase, to analyze the Env-mediate cell-cell fusion (44). The function of an inactive mutant β -galactosidase with N-terminal residues 11-41 deleted (ω fragment) is rescued by its N-terminal fragment, called the α fragment, upon Env-mediated cell-cell fusion. 293T cells were cotransfected with either HIV-1 Env and the α fragment of β -galactosidase or CD4,

CCR5 and the ω fragment of β -galactosidase. Env-expressing cells (2.0×10^6 cells/ml) were mixed with CD4- and CCR5-expressing cells (2.0×10^6 cells/ml). Cell-cell fusion was allowed to proceed at 37°C for 2 hr. Cell-cell fusion activity was quantified using a chemiluminescent assay system, Gal-Screen (Applied Biosystems, Foster City, CA). Background signal was determined by carrying out the assay with cells lacking the Env gene. To analyze antibody inhibition, Env-expressing cells were first incubated with antibodies at various concentrations (62.5 nM - 1 μ M) at 37°C for 20 min before mixing with CD4- and CCR5-expressing cells. Antibodies used in this assay include Fab fragments of b6, 3791, 17b, PG9, PG16, PGT145 and VRC01.

Viral infectivity and antibody neutralization assays

Viral infectivity of HIV-1 92UG037.8 Env and its TMD mutants was measured by infecting TZM.bl cells with p24-normalized pseudovirus in growth media containing DEAE-dextran (11 μ g/ml). 48 hours post-infection, luciferase activity of the reporter gene was quantified as previously described (45). Likewise, neutralizing IC₅₀ and IC₈₀ titers of monoclonal antibodies were determined also by the luciferase-based virus neutralization assay in TZM.bl cells as previously described (45). The assay measures the reduction in luciferase reporter gene expression in TZM-bl cells following a single round of virus infection. Briefly, 5-fold serial dilutions of antibody samples were performed in duplicate (96-well flat bottom plate) in 10% DMEM growth medium (100 μ l/well). Virus was added to each well in a volume of 50 μ l, and the plates were incubated for 1 hour at 37°C. TZM.bl cells were then added (1×10^4 /well in 100 μ l volume) in 10% DMEM growth medium containing DEAE-Dextran. Following a 48 hour incubation, luminescence was measured using Bright-Glo luciferase reagent (Promega, Madison, WI). The IC₅₀ and IC₈₀ titers were calculated as the antibody dilution that resulted in a 50% or 80% reduction in relative luminescence units (RLU), respectively, compared with the virus control wells after the subtraction of cell control RLU. Maximum percent inhibition (MPI) indicates the highest percent inhibition of virus infection observed with the tested concentrations of each antibody. Murine leukemia virus (MuLV) was used as a negative control virus for all assays. Antibodies used in this assay include IgG of b6, 3791, 17b, PG9, PG16, PGT145 and 3BNC117.

Fig. S1




Figure S1. Schematic and sequence of the transmembrane segment of Env. (A) Schematic representation of HIV-1 Env trimer with gp120 in green, gp41 ectodomain in blue, the transmembrane domain (TMD) in magenta, and the cytoplasmic tail in red. **(B)** Location of the transmembrane segment in the gp160 schematic and sequence alignment of the HIV-1 gp41 fragment (residues 677-716; HXB2 numbering) from four selected isolates used in this study. The first three sequences were chosen because of their suitability for NMR studies and the 92UG037.8 sequence was used for functional studies. The 92BR025.9 construct contains M687K mutation, necessary for CNBr cleavage reaction during protein purification. The schematic is shown in the same color scheme as in (A) and the alignment is colored by ClustalW. **(C)** Sequence logos showing variations

in the gp41 segment (residues 677-716) among 5132 HIV-1 sequences (top), 113 HIV-2 sequences (middle) and 173 SIV sequences (bottom panel). They are colored according to their chemical properties: small amino acids are in green, hydrophobic amino acids in black, and strongly polar or charged basic residues in blue. The logos were generated using website tools of the Los Alamos National Laboratory, New Mexico, USA (http://www.hiv.lanl.gov/content/sequence/ANALYZEALIGN/analyze_align.html), as recommended by Dr. Bette Korber (Los Alamos National Laboratory).

Fig. S2




Figure S2. Purification and bicelle reconstitution of gp41^{HIV1D (677-716)}. (A) Reverse-phase HPLC purification of gp41^{HIV1D (677-716)} after cleavage from the TrpLE fused protein. (B) The 1D ¹H NMR spectrum of a bicelle reconstituted gp41^{HIV1D (677-716)} sample recorded at 600 MHz showing the molar ratio of DMPC to DHPC as ~ 0.5. (C) Illustration of gp41^{HIV1D (677-716)} trimer in a DMPC (blue spheres)/DHPC (cyan spheres) bicelle. The radius of the bicelle is calculated using the displayed equation (20), in which, R and r are radii of planar and rim region, respectively; q is the molar ratio of DMPC to DHPC; and k is the ratio of headgroup areas for DHPC as compared with DMPC. The diameter ($2R$) of the planar region of a bicelle is calculated to be ~44 Å when $q = 0.5$. (D) MALDI-TOF mass spectrometry (left) of gp41^{HIV1D (677-716)}. The pure lyophilized protein was dissolved in isopropanol for mass spectrometry, giving an expected size of a monomer (theoretical M.W. of monomer is 4.7 kDa). SDS-PAGE (right) of bicelle-reconstituted gp41^{HIV1D (677-716)}. The protein migrates between the markers of 14 and 18 kDa and the calculated M.W. of trimer is ~14.1 kDa.

Fig. S3




Figure S3. NMR spectra of gp41(677-716) derived from different HIV-1 isolates.

Two-dimensional ^1H - ^{15}N TROSY-HSQC spectra of bicelle-reconstituted gp41(677-716) samples: (^2H , ^{15}N)-labeled sample from the HIV-1 clade D isolate 92UG024.2 (**A**), (^2H , ^{15}N)-labeled sample from the clade G isolate 92RU131.16 (**B**), and ^{15}N -labeled sample from the clade C isolate 92BR025.9 (with M687K mutation) (**C**). All spectra were recorded at ^1H frequency of 600 MHz. Assignment of backbone amide resonances are shown for gp41(677-716) from clade D 92UG024.2 (gp41^{HIV1D (677-716)}).

Fig. S4




Figure S4. NMR spectra of gp41^{HIV1D (677-716)} sidechain groups. **(A)** The 2D ¹H-¹³C HSQC (28 ms ¹³C constant time) recorded at 900 MHz showing the assignments of methyl group resonances of gp41^{HIV1D (677-716)} trimer in bicelles (with deuterated DMPC and DHPC). **(B)** NOE strips of the four Arg side chain epsilon protons from the 3D ¹⁵N-edited NOESY-TROSY-HSQC spectrum. The spectrum was recorded with NOE mixing time of 60 ms at ¹H frequency of 600 MHz. The sample used consists of uniformly (¹⁵N, ¹³C)-labeled protein reconstituted in DMPC/DHPC bicelles (q = 0.5), in which the acyl chains of DMPC and DHPC were deuterated. The assignments of the diagonal peaks are shown in red.

Fig. S5




Figure S5. Intermonomer NOEs from the mixed isotope labeled gp41^{HIV1D(677-716)}. Residue-specific strips taken from the 3D ¹⁵N-edited NOESY-TROSY-HSQC spectrum (NOE mixing time = 300 ms) recorded at 750 MHz using the bicelle-reconstituted gp41^{HIV1D(677-716)} sample containing 50% (¹⁵N, ²H)-labeled protein and 50% (15% ¹³C)-labeled protein. The crosspeaks in the aliphatic regions are intermonomer NOEs between the backbone amide and the sidechain methyl protons. The strips corresponding to the indole amines of W678 and W680 show NOEs to almost all the protons of the non-deuterated phospholipid headgroup, suggesting that the tryptophans reside within the headgroup region of the bicelle. The methyl group chemical shifts in the TM region are very similar in the proton dimension. The methyl NOE crosspeaks were initially assigned based on the assumption that the three equivalent TM helices form parallel trimers, i.e., intermonomer NOEs can only be between residues that are nearby along the amino acid sequence. These NOE assignments were subsequently validated and complemented by self-consistent NOEs from the ¹³C- and ¹⁵N-edited NOESYs (900 MHz) of a uniformly (¹⁵N, ¹³C)-labeled sample.

Fig. S6




Figure S6. Structures of gp41^{HIV1D(677-716)} calculated with NMR restraints. (A) Ribbon representation of the trimer structure showing NOE-derived intermonomer restraints (red lines). **(B)** Ensemble of 15 lowest energy structures calculated using NMR-derived structural restraints (see Table S1). Structures are shown as thin ribbon representation of the backbones. **(C)** Same as in (B) but includes the side chains.

Fig. S7




Figure S7. ^1H linewidth for backbone amide resonances of gp41^{HIV1D(677-716)}. (A) Residue-specific ^1H linewidth of the backbone amide resonances of gp41^{HIV1D(677-716)} derived from the ^1H - ^{15}N TROSY-HSQC spectrum of a (^2H , ^{15}N , ^{13}C)-labeled sample, recorded at 750 MHz. The ^1H linewidths were determined using NMRDraw and overlapped resonances were not analyzed. Mean ^1H linewidths from two spectra are plotted in the graph, with error bars representing the standard deviation. The ^1H linewidths of the N-terminal half of the protein (residues 679-696) are significantly larger ($P=0.0007$, two-tailed unpaired T test) than those of the C-terminal half (residues 698-712). (B) Mapping of ^1H linewidth from (A) onto the gp41^{HIV1D(677-716)} structure.

Fig. S8




Figure S8. SDS-PAGE analysis of purified and reconstituted gp41^{HIV1D(677-716)} mutants. gp41^{HIV1D(677-716)} mutants were purified in the same way as the wildtype protein (described in Materials and Methods), reconstituted in bicelles and analyzed by SDS-

PAGE under non-boiling conditions. For the 704-713 mutant, the sequence of residues 704-713 (VINRVRQGYS) was mutated to SSAASAAGSA.

Fig. S9





Figure S9. Expression and processing of Env mutants expressed in 293T cells. Env samples prepared from 293T cells transiently transfected with 5 µg of the HIV-1 gp92UG037.8 gp160 expression plasmid or each of Env mutants were detected by an anti-V3 antibody 3791. The low level of cleavage of the mutant G435V/V710A may account for its low cell-cell fusion activity and lack of active pseudovirus.

Fig. S10

A



B

Mutation	Mean Fluorescence Intensity (MFI)		
	2G12	VRC01	10E8
wildtype	1211	1046	193
F685A	1430	1206	319
I686A	1311	1084	229
G690A	1762	1488	389
G690L	1443	1215	214
L692A	1833	1529	325
I693A	1547	1242	302
G694A	1602	1400	349
G694V	1633	1343	332
L695A	1731	1387	340
R696A	2099	1793	390
I697A	1892	1623	409
F699A	1882	1629	210
S703K	2084	1803	476
V704N	2265	1877	532
N706A	1387	1165	160
Q710L	1821	1499	353
Y712A	2614	2150	353
P714N	2388	1940	384
N706A/Q710A	1797	1547	347
704-713	2043	1730	369
G690L/S703K	2144	1838	401
G690L/V704N	1802	1541	361
G690L/Y712A	2113	1817	329
G690L/P714N	2034	1694	323
G690L/P714K	2220	1783	449
G690L/P714H	2099	2019	234
G690/704-713	2616	1577	221
V704N/Q710L	1757	1599	406
G690L/V704N/Q710L	1292	1130	173
G435V/Q710A	1112	895	254
293T cell control	27	25	29

Figure S10. Cell-surface expression of Env mutants detected by flow cytometry. (A)

Representative dot plots for negative control 293T cells, cells expressing the wildtype Env (WT), or mutants R696A and 704-713, measured by flow cytometry using monoclonal antibodies 2G12, VRC01 and 10E8. **(B)** Summary of mean fluorescence

intensity (MFI) from data as shown in (A) for the wildtype and 30 Env mutants, as well as the 293T cell control.

Fig. S11




Figure S11. Cell-cell fusion of HIV-1 Env and its TMD mutants at a high expression level. 293T cells transfected with 5 μ g of the 92UG037.8 Env expression plasmid or each of its TMD mutants were fused with CD4- and CCR5-expressing cells. Cell-cell fusion led to reconstitution of active β -galactosidase and thus the fusion activity was quantified by a chemiluminescent assay. No env was a negative control. The experiment was carried out in triplicate and repeated at least twice with similar results. Error bars indicate the standard deviation calculated by the Excel STDEV function. Data points are means \pm standard deviations from triplicate measurements. Under these conditions, cell-cell fusion was not sensitive to inhibition by many neutralizing antibodies, such as PG9, PG16 and PGT145 (data not shown).

Fig. S12




Figure S12. Cell-cell fusion of HIV-1 Env and its TMD mutants at a low expression level. 293T cells transfected with 25 ng of the 92UG037.8 Env expression plasmid or each of its TMD mutants were mixed with CD4- and CCR5-expressing cells. Cell-cell fusion led to reconstitution of active β -galactosidase and thus the fusion activity was quantified by a chemiluminescent assay. No env, no CD4 and no CCR5 were negative controls. The experiment was carried out in triplicate and repeated at least twice with similar results. Error bars indicate the standard deviation calculated by the Excel STDEV function. Data points are means \pm standard deviations from triplicate measurements. The data are also summarized in Table S2.

Fig. S13




Figure S13. Incorporation of Env mutants into pseudoviruses analyzed by western blot. Env samples prepared from p24-normalized pseudoviruses containing either HIV-1 gp92UG037.8 Env or each of its TMD mutants were detected by an anti-V3 antibody 3791.

Fig. S14





Figure S14. Viral infectivity of Env mutants. Pseudoviruses containing Env mutants were normalized by p24-antigen, titrated 10 times using 5-fold dilution series, and tested

for viral infectivity in TZM.bl cells. The Env mutants are grouped in **(A)** for those containing mutations in the coiled-coil; in **(B)** containing mutations of R696 and its surrounding residues; in **(C)** containing mutations in the kink; in **(D)** with mutations in the hydrophilic core; in **(E)** with mutations in the coiled-coil and kink; in **(F)** with mutations in the coiled-coil and hydrophilic core; in **(G)** with mutations in the kink and hydrophilic core; and in **(H)** with mutations in the coiled-coil, kink and hydrophilic core. The experiment was carried out in quadruplicate. Error bars indicate the standard deviation calculated by GraphPad Prism (GraphPad Software, Inc., La Jolla, CA).

Fig. S15 (A-B)

A. Analysis of mutations in the coiled coil of TMD



B. Analysis of mutations of R696 and its surrounding residues of TMD





Fig. S15 (C-D)

C. Analysis of mutations in the kink of TMD



D. Analysis of mutations in the hydrophilic core of TMD





Fig. 15(E-F)

E. Analysis of mutations in the coiled coil/kink of TMD



F. Analysis of mutations in the coiled coil/hydrophilic core of TMD





Fig. S15 (G-H)

G. Analysis of mutations in the kink/hydrophilic core of TMD



H. Analysis of mutations in the coiled coil/kink/hydrophilic core of TMD




Figure S15. Antibody inhibition of cell-cell fusion mediated by the Env TMD

mutants. The trimer-specific bnAb PG16 and non-neutralizing anti-V3 antibody 3791 were used to assess effect of mutations in various structural elements in the TMD on antibody inhibition of Env-mediated cell-cell fusion. The Env mutants are grouped in (A) for those containing mutations in the coiled-coil; in (B) containing mutations of R696 and its surrounding residues; in (C) containing mutations in the kink; in (D) with mutations in the hydrophilic core; in (E) with mutations in the coiled-coil and kink; in (F) with mutations in the coiled-coil and hydrophilic core; in (G) with mutations in the kink and hydrophilic core; and in (H) with mutations in the coiled-coil, kink and hydrophilic core. The experiment was carried out in duplicate and repeated at least twice with similar results.

Fig. S16




Figure S16. Antibody inhibition of cell-cell fusion mediated by the WT Env and mutant 704-713. Cell-cell fusion mediated by the wildtype 92UG037.8 Env (left) or the mutant 704-713 (right) was inhibited by non-neutralizing antibodies b6 (CD4 binding site), 3791 (V3) and 17b (CD4-induced), and trimer-specific bnAbs, PG9, PG16 and PGT145, respectively. The CD4 binding site bnAb VRC01 was a control antibody. The experiment was carried out in triplicate and repeated at least twice with similar results. Error bars indicate the standard deviation calculated by the Excel STDEV function. The data were summarized in Figure 3A.

Fig. S17




Figure S17. Antibody inhibition of cell-cell fusion mediated by the WT Env and mutant 704-713 derived from a clade C HIV-1 isolate C97ZA012. (A) Antibody inhibition of cell-cell fusion mediated by the wildtype C97ZA012 Env (left) and its TMD mutant 704-713 (right; residues 704-713 (IVNRVRQGYS) were mutated to SSAASAAGSA.) was analyzed using both non-neutralizing antibodies, including b6 (CD4 binding site; blue), 3791 (V3; cyan) and 17b (CD4-induced; purple), and trimer-specific bnAbs, including PG9 (orange), PG16 (red) and PGT145 (magenta). The C97ZA012 Env is totally resistant to antibody b6. The experiment was carried out in duplicate and repeated twice. (B) Raw data for (A).

Fig. S18




Fig. S18 (continued)




Figure S18. Backbone dihedral angles of residues in gp41^{HIV1D(677-716)}. Ramachandran plots showing the backbone dihedral angles, ϕ and ψ , and their respective uncertainties. The dihedrals were derived by TALOS+ using N, C α , and C' chemical shifts. Among the

residues analyzed, all except G711 and L715 were considered “Good” by TALOS+. The Good dihedral angles and uncertainties were used as restraints in XPLOR calculation.

Fig. S19




Figure S19. Backbone secondary Cα chemical shifts for each residue. The difference between backbone Cα chemical shifts (of each amino acid in gp41^{HIV1D(677-716)}) to the random coil Cα chemical shift is plotted as the secondary Cα chemical shift. The random coil Cα values were obtained from the Biological Magnetic Resonance Data Bank (<http://www.bmrb.wisc.edu/>).

Fig. S20




Figure S20. NOEs to the side chain of R696. (A) NOE strips from ^{15}N -edited and ^{13}C -edited NOESYs showing key NOEs that define the side chain conformation of R696. **(B)** Position of L695 and L692 with respect to R696.

Table S1**Table S1. NMR and refinement statistics**

NMR distance and dihedral constraints^a	
Distance constraints from NOE	585
Short-range intramolecular ($ i - j \leq 4$)	498
Long-range intramolecular ($ i - j \geq 5$)	3
Intermolecular	84
Total dihedral angle restraints ^b	210
ϕ (TALOS)	105
ψ (TALOS)	105
Structure statistics^c	
Violations (mean \pm s.d.)	
Distance constraints (Å)	0.217 \pm 0.006
Dihedral angle constraints (°)	2.167 \pm 0.108
Deviations from idealized geometry	
Bond lengths (Å)	0.033 \pm 0.000
Bond angles (°)	1.669 \pm 0.024
Impropers (°)	1.010 \pm 0.025
Average pairwise r.m.s. deviation (Å) ^d	
Heavy	1.442
Backbone	0.946

^aThe numbers of constraints are summed over all three subunits. ^bThe backbone dihedrals that were considered as “Good” by TALOS+ (41) were applied in structure calculation with uncertainties from TALOS+ (see Fig. S17). ^cStatistics are calculated and averaged over an ensemble of the 15 lowest energy structures out of 150 calculated structures. ^dThe precision of the atomic coordinates is defined as the average r.m.s. difference between the 15 final structures and their mean coordinates.

Table S2**Table S2. Functional analysis of mutations in the HIV-1 TMD**

Mutation	Structural element	Cell-cell fusion ^a	Viral infectivity ^b
wildtype	n/a	100.0±2.1	100.0±12.6
F685A	coiled-coil	110.7±0.5	80.2±3.5
I686A		44.3±0.7	30.2±0.2
G690A		80.1±5.3	95.0±3.2
G690L		89.3±1.3	80.6±4.6
L692A		106.8±1.4	81.2±2.8
I693A		80.0±3.8	81.8±5.9
G694A		119.2±0.7	100.2±4.5
G694V		103.2±1.7	104.3±5.9
L695A	R696 and its surrounding residues	71.4±0.0	85.6±5.1
R696A		52.0±0.6	97.3±3.7
I697A		99.4±2.4	99.8±3.0
F699A		60.1±1.1	115.8±7.2
S703K	kink	94.8±3.5	102.4±4.0
V704N		81.8±2.3	87.7±8.0
N706A	hydrophilic core	58.5±2.7	89.6±4.4
Q710L		86.3±5.2	90.5±2.9
Y712A		118.4±0.7	92.0±4.2
P714N		101.3±2.5	102.8±7.7
N706A/Q710A		63.8±0.6	96.6±2.4
704-713 ^c		94.8±2.8	17.4±0.3
G690L/S703K	coiled-coil/kink	82.6±5.1	91.7±3.4
G690L/V704N		45.4±1.5	61.7±2.8
G690L/Y712A	coiled-coil/hydrophilic core	103.4±3.8	65.4±3.1
G690L/P714N		85.5±2.7	81.3±6.7
G690L/P714K		108.9±3.2	106.0±12.6
G690L/P714H		88.7±1.3	85.5±5.8
G690L/704-713		105.2±2.2	9.8±0.2
V704N/Q710L	kink/hydrophilic core	71.5±0.6	83.8±3.8
G690L/V704N/Q710L	coiled-coil/kink/hydrophilic core	98.2±3.3	73.3±3.0
G435V/Q710A ^d	gp120/gp41	5.8±0.2	<0.1

^aCell-cell fusion assay was performed in triplicate at a low Env expression level to mimic HIV-1 virions and the original data are shown in Figure S12. ^bViral infectivity assay was performed in quadruplicate using p24-normalized pseudoviruses and titration data for each virus with 5-fold dilution series are also shown in Figure S14. ^c704-713, residues 704-713 (VINRVRQGYS) were mutated to SSAASAAGSA. ^dMutant G435V/Q710A was created accidentally with a mutation in gp120 and used as a control. Data points are means ± standard deviations from triplicate measurements.

Table S3**Table S3. List of monoclonal antibodies targeting HIV-1 Env used in this study.**

Epitope	antibody	reference
CD4 binding site	VRC01, 3BNC117 and b6	ref (46)
N160 glycan dependent, trimer-specific epitope	PG9, PG16 and PGT145	ref (47, 48)
N332 glycan dependent epitope	10-1074	ref (49)
CD4i epitope	17b	ref (50)
V3	3791	ref (51)
MPER	10E8	ref (52)

Table S4

Table S4. Antibody neutralization of Env mutants.

Mutant	3791			PG9			3BNC117			10-1074			10E8		
	IC ₅₀	IC ₈₀	MPI	IC ₅₀	IC ₈₀	MPI	IC ₅₀	IC ₈₀	MPI	IC ₅₀	IC ₈₀	MPI	IC ₅₀	IC ₈₀	MPI
wildtype	>50	>50	13	0.016	0.073	99	0.014	0.052	100	0.070	0.241	100	0.424	2.154	100
F685A	>50	>50	1	0.018	0.073	100	0.028	0.090	100	0.070	0.254	100	0.034	0.276	100
I686A	>50	>50	39	0.030	0.240	89	0.009	0.040	100	0.082	0.262	100	0.119	0.828	99
G690A	>50	>50	13	0.016	0.077	99	0.016	0.046	100	0.074	0.252	100	0.498	2.412	100
G690L	>50	>50	21	0.022	0.118	96	0.013	0.047	100	0.081	0.264	100	0.036	0.263	100
L692A	>50	>50	2	0.021	0.076	99	0.019	0.066	100	0.080	0.278	100	0.578	4.435	100
I693A	>50	>50	1	0.023	0.104	99	0.020	0.070	100	0.096	0.321	100	1.166	5.508	100
G694A	>50	>50	12	0.018	0.071	99	0.022	0.063	100	0.092	0.308	100	0.437	3.187	100
G694V	>50	>50	19	0.020	0.071	99	0.018	0.053	100	0.108	0.366	100	0.236	1.806	100
L695A	>50	>50	11	0.032	0.114	99	0.015	0.050	100	0.087	0.384	100	0.266	1.880	100
R696A	>50	>50	8	0.019	0.056	99	0.014	0.034	100	0.065	0.168	100	0.032	0.162	100
I697A	>50	>50	5	0.022	0.090	99	0.017	0.061	100	0.118	0.356	100	0.424	1.638	100
F699A	>50	>50	19	0.019	0.103	95	0.006	0.022	100	0.039	0.138	100	0.001	0.022	100
S703K	>50	>50	31	0.030	0.137	99	0.034	0.104	100	0.126	0.341	100	0.089	0.590	100
V704N	>50	>50	30	0.032	0.086	91	0.025	0.074	100	0.127	0.422	100	0.010	0.089	100
N706A	>50	>50	14	0.007	0.055	98	0.015	0.064	100	0.086	0.331	100	0.042	0.519	100
Q710L	>50	>50	16	0.014	0.097	99	0.020	0.075	100	0.117	0.417	100	0.049	0.433	100
Y712A	>50	>50	37	0.016	0.060	100	0.007	0.032	100	0.052	0.167	100	0.031	0.183	100
P714N	>50	>50	19	0.013	0.087	99	0.015	0.050	100	0.070	0.249	100	0.026	0.244	100
N706A/Q710A	>50	>50	1	0.021	0.119	98	0.019	0.069	100	0.145	0.490	100	0.385	2.498	100
704-713	1.594	>50	66	0.834	>50	68	0.007	0.029	100	0.095	0.257	100	0.004	0.041	100
G690L/S703K	>50	>50	19	0.022	0.169	96	0.010	0.045	100	0.074	0.258	100	0.017	0.126	100
G690L/V704N	>50	>50	44	0.044	18.130	81	0.012	0.042	100	0.102	0.337	100	0.013	0.053	100
G690L/Y712A	>50	>50	4	0.016	0.099	93	0.009	0.032	100	0.084	0.284	100	0.018	0.170	100
G690L/P714N	>50	>50	10	0.025	0.116	92	0.013	0.028	100	0.064	0.207	100	0.013	0.053	100
G690L/P714K	>50	>50	14	0.022	0.094	93	0.017	0.050	100	0.108	0.370	100	0.021	0.178	100
G690L/P714H	>50	>50	14	0.030	0.129	95	0.012	0.041	100	0.090	0.288	100	0.020	0.101	100
G690/704-713	0.016	>50	77	0.059	>50	63	<0.001	<0.001	100	0.041	0.155	100	0.002	0.024	100
V704N/Q710L	>50	>50	33	0.041	0.900	90	0.015	0.061	100	0.137	0.387	100	0.010	0.077	100
G690L/V704N/Q710L	35.223	>50	52	0.118	>50	77	0.022	0.061	100	0.139	0.457	100	0.008	0.084	100